



August 12, 2021

**National Stock Exchange of India Limited,**  
Compliance Department,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (East), Mumbai - 400051,  
Maharashtra, India

**BSE Limited,**  
Compliance Department,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai - 400001,  
Maharashtra, India

Dear Sir/Madam,

**Subject : Disclosure of the Outcome of the Meeting of the Board of Directors of HealthCare Global Enterprises Limited (“the Company”) held on August 12, 2021**

**Stock Code : BSE – 539787, NSE – HCG**

**Reference : Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

We wish to inform you that the Board of Directors of the Company (“Board”), at their meeting held on this day, August 12, 2021, *inter alia*, has considered and approved the following agenda:

1. Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2021;
2. Issue and allotment of 22,540 (Twenty Two Thousand Five Hundred Forty) equity shares of the Company of Rs. 10 each, upon exercise of Employee Stock Options in accordance with the Employee Stock Option Scheme 2014.
3. Appointment of Mr. Rajagopalan Raghavan (DIN: 03627923) as an Additional Director - Independent Non-Executive Director for a term of 3 years with effect from August 12, 2021, who shall not be liable to retire by rotation. The Company shall make detailed disclosure under Regulation 30 of SEBI LODR Regulations with respect to the above matters, as applicable.

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the following:

1. Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2021;
2. Limited Review Report of the Statutory Auditors on the Standalone and Consolidated Financial Results for the quarter ended June 30, 2021.



The Meeting of the Board of Directors commenced at 10.30 a.m. and concluded at 5.15 p.m.

Kindly take the intimation on record and acknowledge receipt of the same.

Thanking you,

For **HealthCare Global Enterprises Limited**

A handwritten signature in blue ink, appearing to read 'Sunu Manuel'.

**Sunu Manuel**  
**Company Secretary & Compliance Officer**

**Encl: a/a.**

# B S R & Co. LLP

Chartered Accountants

Embassy Golf Links Business Park,  
Pebble Beach, B Block, 3<sup>rd</sup> Floor,  
Off Intermediate Ring Road,  
Bengaluru-560 071 India

Telephone: + 91 80 4682 3000  
Fax: + 91 80 4682 3999

## Limited review report on unaudited quarterly consolidated financial results of HealthCare Global Enterprises Limited pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)

To  
Board of Directors of HealthCare Global Enterprises Limited


1. We have reviewed the accompanying Statement of unaudited consolidated financial results of HealthCare Global Enterprises Limited (“the Parent”) and its subsidiaries (the Parent and its subsidiaries together referred to as “the Group”), and its share of the net loss after tax and total comprehensive income of its associate and a joint venture for the quarter ended 30 June 2021 (“the Statement”), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”).
2. This Statement, which is the responsibility of the Parent’s management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

**Limited review report on unaudited quarterly consolidated financial results of HealthCare Global Enterprises Limited pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) (continued)**

4. The Statement includes the results of the following entities:

SI. No.	Name of the Entity	Subsidiary/ Associate/ Joint Venture	Country of incorporation
1	BACC Healthcare Private Limited	Subsidiary	India
2	HCG Medi-Surge Hospitals Private Limited	Subsidiary	India
3	HCG Oncology LLP	Subsidiary	India
4	HealthCare Diwan Chand Imaging LLP	Subsidiary	India
5	HCG NCHRI Oncology LLP	Subsidiary	India
6	HCG EKO Oncology LLP	Subsidiary	India
7	APEX HCG Oncology Hospitals LLP	Subsidiary	India
8	HCG Manavata Oncology LLP	Subsidiary	India
9	Niruja Product Development & Healthcare Research Private Limited	Subsidiary	India
10	HealthCare Global Senthil Multi Specialty Private Limited	Subsidiary	India
11	Malnad Hospital & Institute of Oncology Private Limited	Subsidiary	India
12	HCG Sun Hospitals LLP	Subsidiary	India
13	HCG (Mauritius) Private Limited	Step-down subsidiary	Mauritius
14	HealthCare Global (Africa) Private Limited Group	Associate	Mauritius
15	Strand Life Sciences Private Limited	Joint Venture	India

5. Attention is drawn to the fact that the figures for the 3 months ended 31 March 2021 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. 

**Limited review report on unaudited quarterly consolidated financial results of HealthCare Global Enterprises Limited pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) (continued)**

7. We draw attention to Note 3 in the unaudited consolidated financial results, which describes the economic and social consequences the Group is facing as a result of COVID-19 which is impacting supply chains/demand/personnel available for work and/or being able to access offices/hospitals. Our conclusion is not modified in respect of this matter.
  
8. We did not review the financial information / financial results of six (6) subsidiaries and one (1) step down subsidiary included in the Statement, whose financial information / financial results reflect total revenues of Rs 2,627 lakhs, total net loss after tax of Rs 803 lakhs and total comprehensive loss of Rs 797 lakhs, for the quarter ended 30 June 2021, as considered in the consolidated unaudited financial results. The consolidated unaudited financial results also includes the Group’s share of net profit of Rs. 57 lakhs and total comprehensive income of Rs. 212 lakhs for the quarter ended 30 June 2021, as considered in the Statement, in respect of an associate and a joint venture, whose financial information/ financial results have not been reviewed by us. These financial information / financial results have been reviewed by other auditors whose reports have been furnished to us by the management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, an associate and a joint venture, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matters.

For **B S R & Co. LLP**  
Chartered Accountants  
Firm's Registration No. 101248W/W-100022



**Amit Somani**  
Partner

Membership No. 060154  
UDIN: 21060154AAAABX5010

Place: Bengaluru  
Date: 12 August 2021

**HealthCare Global Enterprises Limited**

CIN : L15200KA1998PLC023489

Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India

Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

**STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2021**

(Rs. in Lakhs except share data)

Sl. No.	Particulars	Quarter ended 30 June 2021	Preceding quarter ended 31 March 2021	Corresponding quarter ended in the previous year 30 June 2020	Previous year ended 31 March 2021
		Unaudited	(Refer note 2)	Unaudited	Audited
<b>1</b>	<b>Income</b>				
	(a) Revenue from operations	32,242	29,704	19,235	100,919
	(b) Income from government grant	72	101	111	425
	(c) Other income	344	440	272	1,695
	<b>Total income</b>	<b>32,658</b>	<b>30,245</b>	<b>19,618</b>	<b>103,039</b>
<b>2</b>	<b>Expenses</b>				
	(a) Purchases of medical and non-medical items	9,330	7,357	4,215	23,816
	(b) Changes in inventories	(1,016)	(38)	255	215
	(c) Employee benefits expense	5,580	5,381	4,188	19,594
	(d) Finance costs	2,638	2,591	3,739	11,917
	(e) Depreciation and amortisation expense	3,778	3,838	3,941	15,922
	(f) Medical consultancy charges	6,709	6,419	4,055	22,175
	(g) Other expenses	6,588	6,750	4,696	22,885
	<b>Total expenses</b>	<b>33,607</b>	<b>32,298</b>	<b>25,089</b>	<b>116,524</b>
<b>3</b>	<b>Loss before share of profit/(loss) of an associate / joint venture, exceptional items and tax (1-2)</b>	<b>(949)</b>	<b>(2,053)</b>	<b>(5,471)</b>	<b>(13,485)</b>
<b>4</b>	<b>Share of profit/(loss) of an associate / joint venture</b>	<b>57</b>	<b>88</b>	<b>(192)</b>	<b>(36)</b>
<b>5</b>	<b>Loss before exceptional items and tax (3+4)</b>	<b>(892)</b>	<b>(1,965)</b>	<b>(5,663)</b>	<b>(13,521)</b>
<b>6</b>	<b>Exceptional items, net (refer note 5)</b>	<b>-</b>	<b>8,470</b>	<b>-</b>	<b>9,345</b>
<b>7</b>	<b>Loss before tax (5-6)</b>	<b>(892)</b>	<b>(10,435)</b>	<b>(5,663)</b>	<b>(22,866)</b>
<b>8</b>	<b>Tax expense</b>				
	- Current tax	144	340	10	471
	- Deferred tax (refer note 6)	216	601	(1,112)	(1,227)
	<b>Total tax expense/ (credit)</b>	<b>360</b>	<b>941</b>	<b>(1,102)</b>	<b>(756)</b>
<b>9</b>	<b>Loss for the period / year (7-8)</b>	<b>(1,252)</b>	<b>(11,376)</b>	<b>(4,561)</b>	<b>(22,110)</b>
<b>10</b>	<b>Other comprehensive income / (loss)</b>				
	(i) Items that will not be reclassified subsequently to profit or loss				
	- Remeasurements of the defined benefit plans	-	(47)	-	(47)
	- Income tax effect on (i) above	-	17	-	17
	(ii) Items that will be reclassified to profit or loss				
	- Exchange differences on translation of financial statements of foreign operations	162	(21)	(83)	(202)
	- Effective portion of gain on hedging instruments in a cash flow hedge	116	74	72	447
	- Income tax effect on (ii) above	(41)	(26)	(25)	(156)
	<b>Other comprehensive income / (loss) for the period / year, net of taxes</b>	<b>237</b>	<b>(3)</b>	<b>(36)</b>	<b>59</b>
<b>11</b>	<b>Total comprehensive loss for the period / year (9+10)</b>	<b>(1,015)</b>	<b>(11,379)</b>	<b>(4,597)</b>	<b>(22,051)</b>
	<b>Loss for the period / year attributable to:</b>				
	Owners of the Company	(957)	(10,217)	(3,975)	(19,346)
	Non-controlling interests	(295)	(1,159)	(586)	(2,764)
	<b>Other comprehensive income / (loss) for the period / year attributable to</b>				
	Owners of the Company	237	7	(36)	69
	Non-controlling interests	-	(10)	-	(10)
	<b>Total comprehensive loss for the period / year attributable to</b>				
	Owners of the Company	(720)	(10,210)	(4,011)	(19,277)
	Non-controlling interests	(295)	(1,169)	(586)	(2,774)
<b>12</b>	<b>Paid-up equity share capital (Face value of Rs. 10 each)</b>	<b>12,539</b>	<b>12,536</b>	<b>8,869</b>	<b>12,536</b>
<b>13</b>	<b>Reserves, i.e., 'Other equity'</b>				<b>57,182</b>
<b>14</b>	<b>Loss per share (face value of Rs. 10 each)</b>	<b>Not annualised</b>	<b>Not annualised</b>	<b>Not annualised</b>	<b>Annualised</b>
	(a) Basic	(0.76)	(8.14)	(4.48)	(17.02)
	(b) Diluted *	(0.76)	(8.14)	(4.48)	(17.02)
	* Since there is a loss, potential equity shares are not considered as dilutive and hence Diluted loss per share is same as Basic loss per share.				
	See accompanying notes to the Consolidated Financial Results				



HealthCare Global Enterprises Limited

CIN : L15200KA1998PLC023489

Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India

Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2021

Notes:

- 1 The statement of unaudited consolidated financial results ('the Statement') of HealthCare Global Enterprises Limited ('the Company'), its subsidiaries (collectively referred to as 'the Group'), its associate and its joint venture, for the quarter ended 30 June 2021 has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 12 August 2021. The Statement has been prepared in accordance with Indian Accounting Standards (Ind AS) as notified by the Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules 2015, as amended and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure requirements) Regulations, 2015.

The Statement has been subjected to limited review by the statutory auditors of the Company. The review report of the auditors is unqualified.

- 2 The figures for preceding quarter ended 31 March 2021 are the balancing figures between audited figures in respect of the full previous financial year and the published unaudited year to date figures upto the end of the third quarter of the previous financial year, which were subject to limited review by the statutory auditor of the Company.

3 Impact of COVID 19 pandemic:

The number of new cases of Covid which had reached its lowest level in the first week of February 2021, increased in March 2021. The Group has taken necessary actions to secure the health and safety of its employees and extended ecosystem. While different forms of restrictions were imposed by various state governments and local bodies to control this strong second wave of the pandemic, these restrictions are not as severe as the lockdown during first wave. The Group's operations are currently running at normal levels. However, the Group will continue to monitor changes to the future economic conditions for any material impact as the situation evolves including its new projects.

The Group has incurred losses in the current quarter. Management believes that it has taken into account the possible impacts of known events arising from COVID-19 pandemic in the preparation of the financial results including but not limited to its assessment of the Group's liquidity position and various estimates in relation to the financial results captions upto the date of adoption of Statement by the Board of Directors. Given the nature and duration of COVID-19, its impact on the financial results may differ from that estimated as at the date of approval of these financial results.

- 4 a) During the previous year ended 31 March 2021, the Company made preferential allotment of 29,516,260 Equity shares of the face value of Rs. 10 each, at a premium of Rs. 120 each (aggregating to Rs. 130 per equity share) and 18,560,663 Warrants, with a right to apply for and be allotted one equity share of the face value of Rs. 10 each at a premium of Rs. 120 each (aggregating to Rs. 130 per Warrant) to Aceso Company Pte. Ltd., Singapore ("Investor") on 28 July 2020. As required under the provisions of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the "ICDR Regulations"), Investor remitted an amount Rs. 51,284 lakhs towards allotment of 29,516,260 equity shares at Rs. 130 per share (Rs. 38,371 lakhs), 100% consideration for allotment and subsequent exercise of 7,057,195 warrants at Rs. 130 per warrant (Rs. 9,174 lakhs) that was converted into equity and 25% of the consideration for remaining 11,503,468 warrants at Rs. 130 per warrant (Rs. 3,739 lakhs). The remaining 75% of the consideration i.e. Rs. 11,216 lakhs shall be payable by the Investor on the exercise of the Warrant(s), in one or more tranches, within a period of 18 (Eighteen) months from the date of allotment of the warrants.

b) During the previous year, on 28 July 2020, the Company also made preferential allotment of 2,000,000 Series B Warrants, with a right to apply for and be allotted 1 Equity Share of the face value of Rs. 10 each of the Company, at a premium of Rs. 120 for each series B Warrant (aggregating to Rs. 130 per warrant), to Promoter Shareholder. As required under the provisions of the ICDR Regulations, an amount equivalent to 25% of the consideration i.e., Rs. 650 lakhs was received on issue of series B Warrants and the remaining 75% of the consideration i.e., Rs. 1,950 lakhs shall be payable by him on the exercise of the Series B Warrant(s), in one or more tranches, within a period of 18 (Eighteen) months from the date of allotment of the Series B Warrants.

5 Exceptional items:

a) During the quarter and year ended 31 March 2021, the Group assessed the recoverable value of its investment made in the upcoming greenfield project in Gurgaon. The assessment was made considering significant change in scope, delays in project due to changes in management plan, market conditions including the outbreak of COVID-19 pandemic. The recoverable amount of this project (considering the future cash flows) was estimated to be lower than carrying value, resulting into an impairment charge of Rs. 3,630 lakhs during the year ended 31 March 2021.

b) During the quarter and year ended 31 March 2021, the Group carried out annual impairment assessment with respect to one of its cash generating unit i.e. BACC HealthCare Private Limited (hereinafter referred to as "the CGU"). Considering the losses incurred and more importantly the relatively weaker forecasts due to COVID-19, the Company recorded an impairment loss on goodwill amounting to Rs. 1,300 lakhs.

c) During the previous year ended 31 March 2021, due to changes in business environment and weaker project viability due to COVID-19, the Cochin project was abandoned. Hence an amount of Rs. 875 lakhs was "written off".

d) During the quarter and year ended 31 March 2021, due to COVID-19, the Group assessed the recoverable amount of certain class of assets /investments in other parties and estimated that those class of assets/investments in other parties may not be recoverable, resulting into an impairment charge amounting to Rs. 981 lakhs.

e) During the previous year, CDC Group PLC, (CDC), the other investor in Healthcare Global (Africa) Pvt Ltd, exercised put option to sell its shares in accordance with the terms of Shareholders Agreement. As at 31 March 2021, pending valuation by an independent valuer to ascertain the fair value of such put option shares, the Group assessed the value of put option by using its best estimate and recognised liability of Rs. 380 lakhs. The Group also performed impairment assessment, basis which the recoverable amount of investment was estimated to be lower than carrying value. Accordingly, impairment charge of Rs. 995 lakhs on its investment in Healthcare Global (Africa) Pvt Ltd was recognised during the quarter and year ended 31 March 2021.

f) During the quarter and year ended 31 March 2021 for one lease arrangement, the Group negotiated lower lease rent for reduced space and the resulting gain on modification of Rs. 577 lakhs was recognised.

g) During the quarter and year ended 31 March 2021, for certain subsidiaries, the Group de-recognised the deferred government grant amounting to Rs. 1,130 lakhs and also made an additional provision towards estimated duties and taxes (EPCG Licenses) amounting to Rs. 2,141 lakhs.



HealthCare Global Enterprises Limited

CIN : L15200KA1998PLC023489

Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India

Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2021

Notes: contd.,

- 6 Deferred tax expense for the quarter and year ended 31 March 2021 includes Rs. 861 lakhs being the Deferred Tax Liability recognized by the Group on difference between book base and tax base of goodwill consequent to Finance Act, 2021 since depreciation on goodwill is not available from 1 April 2020 as per the Finance Act, 2021.
- 7 The Code on Social Security 2020 ('Code'), which received the Presidential Assent on 28 September 2020, subsumes nine regulations relating to social security, retirement, and employee benefits. The Code will have an impact on the contributions towards gratuity and provident fund made by the Group. The Ministry of Labour and Employment ('Ministry') has released draft rules for the Code on 13 November 2020. The effective date of the Code has not yet been notified and the related rules to ascertain the financial impact are yet to be finalized and notified. The Group will assess the impact once the subject rules are notified and will give appropriate impact in its financial results in the period in which, the Code becomes effective.
- 8 The Group has a single operating segment of 'setting up and managing hospitals and medical diagnostic services'.

For and on behalf of the Board of Directors

  
Dr. B. S. Anilkumar  
Executive Chairman

Bengaluru, 12 August 2021





# B S R & Co. LLP

Chartered Accountants

Embassy Golf Links Business Park,  
Pebble Beach, B Block, 3<sup>rd</sup> Floor,  
Off Intermediate Ring Road,  
Bengaluru-560 071 India

Telephone: + 91 80 4682 3000  
Fax: + 91 80 4682 3999

## **Limited review report on unaudited quarterly standalone financial results of HealthCare Global Enterprises Limited pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)**

To  
Board of Directors of HealthCare Global Enterprises Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of HealthCare Global Enterprises Limited (“the Company”) for the quarter ended 30 June 2021 (“the Statement”).
2. This Statement, which is the responsibility of the Company’s management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the 3 months ended 31 March 2021 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



Page 1 of 2

6. We draw attention to Note 3 in the unaudited standalone financial results, which describes the economic and social consequences the Company is facing as a result of COVID-19 which is impacting supply chains/demand/personnel available for work and/or being able to access offices/hospitals.

Our conclusion is not modified in respect of this matter.

For **B S R & Co. LLP**  
Chartered Accountants  
Firm's Registration No. 101248W/W-100022



**Amit Somani**  
Partner

Membership No.060154  
UDIN: 21060154AAAABY3841

Place: Bengaluru  
Date: 12 August 2021

**HealthCare Global Enterprises Limited**

CIN : L15200KA1998PLC023489

Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India

Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

**STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2021**

(Rs. in Lakhs except share data)

Sl. No.	Particulars	Quarter ended 30 June 2021	Preceding quarter ended 31 March 2021	Corresponding quarter ended in the previous year 30 June 2020	Previous year ended 31 March 2021
		Unaudited	(Refer note 2)	Unaudited	Audited
1	<b>Income</b>				
	(a) Revenue from operations	20,010	17,890	12,139	60,886
	(b) Income from government grant	50	61	51	217
	(c) Other income	453	460	341	2,185
	<b>Total income</b>	<b>20,513</b>	<b>18,411</b>	<b>12,531</b>	<b>63,288</b>
2	<b>Expenses</b>				
	(a) Purchases of medical and non-medical items	5,862	4,288	2,709	13,790
	(b) Changes in inventories	(711)	(72)	52	56
	(c) Employee benefits expense	3,882	3,774	2,906	13,672
	(d) Finance costs	1,250	1,278	2,299	6,286
	(e) Depreciation and amortisation expense	2,097	2,125	2,185	8,658
	(f) Medical consultancy charges	3,700	3,423	2,142	11,629
	(g) Other expenses	4,240	4,226	3,071	14,392
	<b>Total expenses</b>	<b>20,320</b>	<b>19,042</b>	<b>15,364</b>	<b>68,483</b>
3	<b>Profit / (loss) before exceptional items and tax (1-2)</b>	<b>193</b>	<b>(631)</b>	<b>(2,833)</b>	<b>(5,195)</b>
4	Exceptional items, net (refer note 5)	-	14,435	-	15,310
5	<b>Profit / (loss) before tax (3-4)</b>	<b>193</b>	<b>(15,066)</b>	<b>(2,833)</b>	<b>(20,505)</b>
6	<b>Tax expense</b>				
	- Current tax	43	-	-	-
	- Deferred tax (refer note 6)	10	256	(960)	(1,351)
	<b>Total tax expense/ (credit)</b>	<b>53</b>	<b>256</b>	<b>(960)</b>	<b>(1,351)</b>
7	<b>Profit / (loss) for the period / year (5-6)</b>	<b>140</b>	<b>(15,322)</b>	<b>(1,873)</b>	<b>(19,154)</b>
8	<b>Other comprehensive income / (loss)</b>				
	(i) Items that will not be reclassified subsequently to profit or loss				
	- Remeasurements of the defined benefit plans	-	(21)	-	(21)
	- Income tax effect on (i) above	-	7	-	7
	(ii) Items that will be reclassified to profit or loss				
	- Effective portion of gain on hedging instruments in a cash flow hedge	118	74	72	447
	- Income tax effect on (ii) above	(41)	(26)	(25)	(156)
	<b>Other comprehensive income / (loss) for the period / year, net of tax</b>	<b>77</b>	<b>34</b>	<b>47</b>	<b>277</b>
9	<b>Total comprehensive income / (loss) for the period / year (7+8)</b>	<b>217</b>	<b>(15,288)</b>	<b>(1,826)</b>	<b>(18,877)</b>
10	Paid-up equity share capital (Face value of Rs. 10 each)	12,539	12,536	8,869	12,536
11	Reserves, i.e., 'Other equity'				79,842
12	<b>Earnings / (Loss) per equity share (face value of Rs. 10 each)</b>	<b>Not annualised</b>	<b>Not annualised</b>	<b>Not annualised</b>	<b>Annualised</b>
	(a) Basic	0.11	(12.20)	(2.11)	(16.85)
	(b) Diluted	0.11	(12.20)*	(2.11)*	(16.85)*
	* Since there is a loss during previous year / period, potential equity shares are not considered as dilutive and accordingly diluted loss per share is same as basic loss per share.				
	See accompanying notes to the Standalone Financial Results				

*ASJ*



HealthCare Global Enterprises Limited

CIN : LI5200KA1998PLC023489

Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India

Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2021

Notes:

1 The statement of unaudited standalone financial results ('the Statement') of HealthCare Global Enterprises Limited ('the Company') for the quarter ended 30 June 2021 has been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on 12 August 2021. The Statement has been prepared in accordance with Indian Accounting Standards (Ind AS) as notified by the Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules 2015, as amended and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure requirements) Regulations, 2015

The Statement has been subjected to limited review by the statutory auditors of the Company. The review report of the auditors is unqualified.

2 The figures for preceding quarter ended 31 March 2021 are the balancing figures between audited figures in respect of the full previous financial year and the published unaudited year to date figures upto the end of the third quarter of the previous financial year, which were subject to limited review by the statutory auditor of the Company.

3 Impact of COVID 19 pandemic:

The number of new cases of Covid which had reached its lowest level in the first week of February 2021, increased in March 2021. The Company has taken necessary actions to secure the health and safety of its employees and extended ecosystem. While different forms of restrictions were imposed by various state governments and local bodies to control this strong second wave of the pandemic, these restrictions are not as severe as the lockdown during first wave. The Company's operations are currently running at normal levels. However, the Company will continue to monitor changes to the future economic conditions for any material impact as the situation evolves including its new projects.

Management believes that it has taken into account the possible impacts of known events arising from COVID-19 pandemic in the preparation of the financial results including but not limited to its assessment of the Company's liquidity position and various estimates in relation to the financial results captions upto the date of adoption of Statement by the Board of Directors. Given the nature and duration of COVID-19, its impact on the financial results may differ from that estimated as at the date of approval of these financial results.

4 a) During the previous year ended 31 March 2021, the Company made preferential allotment of 29,516,260 Equity shares of the face value of Rs. 10 each, at a premium of Rs. 120 each (aggregating to Rs. 130 per equity share) and 18,560,663 Warrants, with a right to apply for and be allotted one equity share of the face value of Rs. 10 each at a premium of Rs. 120 each (aggregating to Rs. 130 per Warrant) to Aceso Company Pte. Ltd., Singapore ("Investor") on 28 July 2020. As required under the provisions of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the "ICDR Regulations"), Investor remitted an amount Rs. 51,284 lakhs towards allotment of 29,516,260 equity shares at Rs. 130 per share (Rs. 38,371 lakhs), 100% consideration for allotment and subsequent exercise of 7,057,195 warrants at Rs. 130 per warrant (Rs. 9,174 lakhs) that was converted into equity and 25% of the consideration for remaining 11,503,468 warrants at Rs. 130 per warrant (Rs. 3,739 lakhs). The remaining 75% of the consideration i.e. Rs. 11,216 lakhs shall be payable by the Investor on the exercise of the Warrant(s), in one or more tranches, within a period of 18 (Eighteen) months from the date of allotment of the warrants.

b) During the previous year, on 28 July 2020, the Company also made preferential allotment of 2,000,000 Series B Warrants, with a right to apply for and be allotted 1 Equity Share of the face value of Rs. 10 each of the Company, at a premium of Rs. 120 for each series B Warrant (aggregating to Rs. 130 per warrant), to Promoter Shareholder. As required under the provisions of the ICDR Regulations, an amount equivalent to 25% of the consideration i.e., Rs. 650 lakhs was received on issue of series B Warrants and the remaining 75% of the consideration i.e., Rs. 1,950 lakhs shall be payable by him on the exercise of the Series B Warrant(s), in one or more tranches, within a period of 18 (Eighteen) months from the date of allotment of the Series B Warrants.

5 Exceptional items:

a) During the quarter and year ended 31 March 2021, the Company performed impairment assessment for all its investments in the subsidiaries, joint ventures and other parties. Given the continued losses incurred and weaker forecasts primarily due to COVID-19, the recoverable amount of investments (considering the future cash flows) was estimated to be lower than their carrying value, resulting into an impairment charge with respect to BACC HealthCare Private Limited amounting to Rs. 5,884 lakhs, Apex HCG Oncology Hospitals LLP amounting to Rs. 1,600 lakhs, HCG EKO Oncology LLP amounting to Rs. 120 lakhs and other parties amounting to Rs. 176 lakhs respectively.

b) During the quarter and year ended 31 March 2021, the Company assessed the recoverable value of its investment made in the upcoming greenfield project in Gurgaon. The assessment was made considering significant change in scope, delays in project due to changes in management plan, market conditions including the outbreak of COVID-19 pandemic. The recoverable amount of this project (considering the future cash flows) was estimated to be lower than carrying value, resulting into an impairment charge of Rs. 3,630 lakhs during the year ended 31 March 2021.

c) During the previous year ended 31 March 2021, due to changes in business environment and weaker project viability due to COVID-19, the Cochin project was abandoned. Hence an amount of Rs. 875 lakhs was "written off".

d) During the quarter and year ended 31 March 2021, due to COVID-19, the Company assessed the recoverable amount of certain class of assets and estimated that those class of assets may not be recoverable, resulting into an impairment charge amounting to Rs. 805 lakhs.

e) The Company has invested in Healthcare Global (Africa) Pvt Ltd ('HCG Africa') through its wholly owned subsidiaries. During the previous year, CDC Group PLC, ('CDC') (other investor in HCG Africa) exercised the put option in accordance with the agreement to exit HCG Africa. The Company performed impairment assessment basis which the recoverable amount of investment/related loans was estimated to be lower than carrying value. Accordingly, loan along with interest accrued of Rs. 2,797 lakhs was impaired during the quarter and year ended 31 March 2021.

f) During the quarter and year ended 31 March 2021 for one lease arrangement, the Company negotiated lower lease rent for reduced space and the resulting gain on modification of Rs. 577 lakhs was recognised.

6 Deferred tax expense for the quarter and year ended 31 March 2021 includes Rs. 861 lakhs being the Deferred Tax Liability recognized by the Company on difference between book base and tax base of goodwill consequent to Finance Act, 2021 since depreciation on goodwill is not available from 1 April 2020 as per the Finance Act, 2021.

7 The Code on Social Security 2020 ('Code'), which received the Presidential Assent on 28 September 2020, subsumes nine regulations relating to social security, retirement, and employee benefits. The Code will have an impact on the contributions towards gratuity and provident fund made by the Company. The Ministry of Labour and Employment ('Ministry') has released draft rules for the Code on 13 November 2020. The effective date of the Code has not yet been notified and the related rules to ascertain the financial impact are yet to be finalized and notified. The Company will assess the impact once the subject rules are notified and will give appropriate impact in its financial results in the period in which, the Code becomes effective.

8 The Company has a single operating segment of 'setting up and managing hospitals and medical diagnostic services'.

Bengaluru, 12 August 2021

  
Dr. B. S. Ajaiyimal  
Executive Chairman

